Low Cost of Goods
Reliable
Versatile

Senior Quality Advisor, Novo Nordisk A/S. M.Sc. and Ph.D. in chemical engineering. 30+ years of pharma management experience from Novo Nordisk, hereof sixteen years in SVP positions i.a. positions with global Novo Nordisk responsibility for business development, device R&D, clinical drug development and quality. During nine years Chairman of the Board in Møller & Devicon A/S, special machine manufacturer to pharma industry

E*MBA from SIMI, HD (A) from Copenhagen Business School. 25 years of experience in leadership, strategy and business development.
International experience from IT, Electronics and MedTech industry. Regional Leadership positions in Creative Labs and SVP position in Daymen Acquisition S.A

Former Global Head of Medical Device Development for Sanofi. Professional Engineer with more than twenty-five years of experience in medical devices. Extensive experience in the design, development, manufacturing and lifecycle management of medical devices, including Lantus SoloStar. Active member of the International Standards Organisation and currently co-chair of TC84.

Managing Partner in VF Venture, invest from seed- to late stage venture capital in IT, MedTech and Industrial technology.

Tonni has extensive global industry operational experience. Previous positions include being CEO of Nordic Medical Group A/S, President, ELA Medical (Canada & South America) and VP USA, a part of Sanofi, Global Marketing Director for St. Jude Medical (Los Angeles, USA, and Japan), BU Director for St. Jude Medical EEMEA (Brussels, Belgium), Country Manager for Guidant Nordic Area and Sales Manager for Danica Biomedical. Educational background: medical engineering and an executive MBA from Scandinavian International Management Institute. On the board of companies like: Reapplix, Microshade, Advalight, TeesuVac, Evosep, Subcuject and FBC Devices.

CEO of Capnova, a Danish pre-seed and seed investor. PhD. Since 1998 Lars has been involved in starting and investing in around 140 new companies of which 50 are spin out’s from university and hospital research. Before 1998 he among other positions was in charge of the profiling of university research towards the industry and managed a governmental cross institutional environmental research program.